JP2012533570A5 - - Google Patents

Download PDF

Info

Publication number
JP2012533570A5
JP2012533570A5 JP2012520827A JP2012520827A JP2012533570A5 JP 2012533570 A5 JP2012533570 A5 JP 2012533570A5 JP 2012520827 A JP2012520827 A JP 2012520827A JP 2012520827 A JP2012520827 A JP 2012520827A JP 2012533570 A5 JP2012533570 A5 JP 2012533570A5
Authority
JP
Japan
Prior art keywords
oxy
ppm
methyloxy
cyclopropane
morpholin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012520827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533570A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/042353 external-priority patent/WO2011009095A1/en
Publication of JP2012533570A publication Critical patent/JP2012533570A/ja
Publication of JP2012533570A5 publication Critical patent/JP2012533570A5/ja
Pending legal-status Critical Current

Links

JP2012520827A 2009-07-17 2010-07-16 N−[3−フルオロ−4−({6−(メチルオキシ)−7−[(3−モルホリン−4−イルプロピル)オキシ]−キノリン−4−イル}オキシ)フェニル]−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶形 Pending JP2012533570A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22650909P 2009-07-17 2009-07-17
US61/226,509 2009-07-17
PCT/US2010/042353 WO2011009095A1 (en) 2009-07-17 2010-07-16 Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide

Publications (2)

Publication Number Publication Date
JP2012533570A JP2012533570A (ja) 2012-12-27
JP2012533570A5 true JP2012533570A5 (cg-RX-API-DMAC7.html) 2013-08-29

Family

ID=42712017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012520827A Pending JP2012533570A (ja) 2009-07-17 2010-07-16 N−[3−フルオロ−4−({6−(メチルオキシ)−7−[(3−モルホリン−4−イルプロピル)オキシ]−キノリン−4−イル}オキシ)フェニル]−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶形

Country Status (15)

Country Link
US (1) US8673912B2 (cg-RX-API-DMAC7.html)
EP (1) EP2454238A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012533570A (cg-RX-API-DMAC7.html)
KR (1) KR20120051702A (cg-RX-API-DMAC7.html)
CN (1) CN102510855B (cg-RX-API-DMAC7.html)
AU (1) AU2010274012A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012001118A2 (cg-RX-API-DMAC7.html)
CA (1) CA2768370A1 (cg-RX-API-DMAC7.html)
EA (1) EA201200144A1 (cg-RX-API-DMAC7.html)
IL (1) IL217537A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012000809A (cg-RX-API-DMAC7.html)
NZ (1) NZ597695A (cg-RX-API-DMAC7.html)
TW (1) TW201118072A (cg-RX-API-DMAC7.html)
WO (1) WO2011009095A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200389B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2392565B1 (en) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
PT2387563E (pt) 2009-01-16 2013-03-25 Exelixis Inc Sal de malato de n-(4-{[6,7-bis(metiloxi)quinolin-4- il]oxi}fenil)-n¿-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, e suas formas cristalinas para o tratamento de cancro
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
SG184040A1 (en) * 2010-03-12 2012-10-30 Exelixis Inc Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
HUE057184T2 (hu) 2010-07-16 2022-04-28 Exelixis Inc C-MET modulátor gyógyszerészeti készítmények
CN103402505A (zh) 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
KR102030447B1 (ko) 2011-02-10 2019-11-08 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
IN2014CN02971A (cg-RX-API-DMAC7.html) 2011-10-20 2015-07-03 Exelixis Inc
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス, インク. 溶骨性骨転移を治療するためのmet−vegf二重調節剤
EP2970126B1 (en) 2013-03-15 2019-03-06 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
US20160082019A1 (en) * 2013-04-04 2016-03-24 Exelixis, Inc. Drug Combinations to Treat Cancer
WO2014165786A1 (en) 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
AU2015218236B2 (en) 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス, インコーポレイテッド カボザンチニブ製剤の投与
WO2016019285A1 (en) 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
KR102634247B1 (ko) 2014-08-05 2024-02-05 엑셀리시스, 인코포레이티드 다발성 골수종을 치료하기 위한 약물 병용물
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
BR112018073667A2 (pt) * 2016-05-16 2019-03-12 Pulmagen Therapeutics (Asthma) Limited cristal de derivado de quinolina
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
US12227536B2 (en) 2018-12-20 2025-02-18 Merck Sharp & Dohme Llc Crystalline forms of an NRTTI compound
CN110357814A (zh) * 2019-07-12 2019-10-22 上海翔锦生物科技有限公司 对甲苯磺酸盐新晶型及其应用
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233736D1 (de) 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP2392565B1 (en) * 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
NZ592827A (en) 2008-11-13 2013-06-28 Exelixis Inc Methods of preparing quinoline derivatives

Similar Documents

Publication Publication Date Title
JP2012533570A5 (cg-RX-API-DMAC7.html)
JP2013522232A5 (cg-RX-API-DMAC7.html)
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
RU2490258C2 (ru) ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90
CA2606719A1 (en) Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same
JP2013535491A5 (cg-RX-API-DMAC7.html)
JP2020521732A5 (cg-RX-API-DMAC7.html)
RU2020111019A (ru) Полиморфная форма tg02
JP2019517487A5 (cg-RX-API-DMAC7.html)
JP2015509537A5 (cg-RX-API-DMAC7.html)
CA2543650A1 (en) A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
JP2018531280A5 (cg-RX-API-DMAC7.html)
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2014508811A5 (cg-RX-API-DMAC7.html)
JP2020531463A5 (cg-RX-API-DMAC7.html)
JP2008525530A5 (cg-RX-API-DMAC7.html)
JP2010501519A5 (cg-RX-API-DMAC7.html)
JP2014520898A5 (cg-RX-API-DMAC7.html)
JP2018516883A5 (cg-RX-API-DMAC7.html)
KR20170048543A (ko) 진정제 및 마취제의 제조에서의 gabaa 수용체 강화제의 용도
JP2012180344A5 (cg-RX-API-DMAC7.html)
JP2011509301A5 (cg-RX-API-DMAC7.html)
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2015522551A5 (cg-RX-API-DMAC7.html)
JP2012509279A5 (cg-RX-API-DMAC7.html)